Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Overview 6 T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Therapeutics Development 7 Products under Development by Stage of Development 7 Products under Development by Therapy Area 8 Products under Development by Indication 9 Products under Development by Companies 10 Products under Development by Universities/Institutes 12 T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Therapeutics Assessment 14 Assessment by Mechanism of Action 14 Assessment by Route of Administration 16 Assessment by Molecule Type 18 T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Companies Involved in Therapeutics Development 20 Amgen Inc 20 GlaxoSmithKline Plc 20 MacroGenics Inc 21 Numab Innovation AG 21 SYNIMMUNE GmbH 22 Tiziana Life Sciences Plc 22 T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Drug Profiles 23 Bispecific Monoclonal Antibodies to Target CD3, CD16 and HBsAg for HBV Infection and Oncology - Drug Profile 23 Product Description 23 Mechanism Of Action 23 R&D Progress 23 foralumab - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 ND-007 - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 otelixizumab - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 TACSYN - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 teplizumab - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 XmAb-13551 - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Dormant Products 34 T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Product Development Milestones 35 Featured News & Press Releases 35 Jul 28, 2017: Publication of Research Article on Foralumab, a Fully Human Anti-CD3 Antibody Being Developed as an Oral Therapy for NASH and Autoimmune Diseases 35 Mar 14, 2017: Tiziana Life Sciences Appoints Dr. Arun Sanyal to its Scientific Advisory Board 35 Nov 18, 2016: New Publication: Partial Exhaustion of CD8 T Cells in Responders to Anti-CD3 Treatment in New-Onset Type 1 Diabetes 36 Nov 16, 2016: Tiziana Life Sciences Announces New Data with Foralumab, a Fully Human Anti-CD3 Antibody Being Developed as an Oral Therapy for NASH and Autoimmune Diseases 36 May 19, 2016: Immunotherapy Journal Review of Anti - CD3 Monoclonal Antibodies Highlights Therapeutic Potential of Tizianas Foralumab 37 Jan 11, 2016: Tiziana announces plans for clinical development of foralumab, the company fully human CD3 antibody 38 Jun 28, 2011: MacroGenics Announces Publication Of Protege Phase III Clinical Data Of Teplizumab In The Lancet 38 Jun 23, 2011: MacroGenics To Present Protege Phase III Clinical Data Of Teplizumab In Type 1 Diabetes At ADA In San Diego, US 39 Mar 11, 2011: Tolerx And GSK Announce Phase III Defend-1 Study Of Otelixizumab In Type 1 Diabetes Fails Primary Endpoint 40 Oct 20, 2010: MacroGenics And Lilly Report Pivotal Clinical Trial Of Teplizumab Did Not Meet Primary Efficacy Endpoint 40 Sep 23, 2010: Tolerx Enrolls First Patient In Europe In DEFEND-2 Phase III Clinical Study For Treatment Of Type 1 Diabetes 41 Sep 23, 2010: Tolerx Presents Baseline Data From DEFEND-1 Study At European Association For Study Of Diabetes Annual Meeting 42 Jun 28, 2010: Tolerx Initiates Confirmatory Phase III Trial With Otelixizumab For Type 1 Diabetes 43 Jun 28, 2010: Tolerx Presents Baseline Data From DEFEND-1 Study Validating C-Peptide As Critical Clinical Measure For New-Onset Type 1 Diabetes 44 Mar 17, 2010: Single Short Course of Tolerx's Otelixizumab Provides Prolonged Preservation Of Beta Cell Function 45 Appendix 46 Methodology 46 Coverage 46 Secondary Research 46 Primary Research 46 Expert Panel Validation 46 Contact Us 46 Disclaimer 47

List of Tables Number of Products under Development by Stage of Development, H2 2017 7 Number of Products under Development by Therapy Areas, H2 2017 8 Number of Products under Development by Indication, H2 2017 9 Number of Products under Development by Companies, H2 2017 10 Products under Development by Companies, H2 2017 11 Number of Products under Investigation by Universities/Institutes, H2 2017 12 Products under Investigation by Universities/Institutes, H2 2017 13 Number of Products by Stage and Mechanism of Actions, H2 2017 15 Number of Products by Stage and Route of Administration, H2 2017 17 Number of Products by Stage and Molecule Type, H2 2017 19 Pipeline by Amgen Inc, H2 2017 20 Pipeline by GlaxoSmithKline Plc, H2 2017 20 Pipeline by MacroGenics Inc, H2 2017 21 Pipeline by Numab Innovation AG, H2 2017 21 Pipeline by SYNIMMUNE GmbH, H2 2017 22 Pipeline by Tiziana Life Sciences Plc, H2 2017 22 Dormant Projects, H2 2017 34

Amgen Inc GlaxoSmithKline Plc MacroGenics Inc Numab Innovation AG SYNIMMUNE GmbH Tiziana Life Sciences Plc